After a trial conducted by UK-based pharmaceutical company GW Pharma, researchers have released startling results. A THC/CBD combo extract was found to improve the survival rate of patients suffering from a kind of brain tumor.
In the placebo-controlled phase 2 study, the cannabis-derived compound was tested on 21 patients afflicted with glioblastoma multiforme. GBM is the most aggressive cancer that begins in the brain and comes with an extremely short life expectancy (one or two years).
During the trial, only 53 percent of trial patients who took placebos survived more than a year. Patients who took GW Pharma’s extract meds, on the other hand, had an 83 percent one-year survival rate, according to Fierce Biotech, which is a more than significant margin of difference.
“Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group,” the pharmaceutical company wrote in a statement released earlier this month.
Almost as important as the results of the study itself are the encouraging possibilities of other cancers THC, CBD and other cannabinoids may have in fighting cancer.
“We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma,” said the company’s CEO Justin Gover.
“These data are a catalyst for the acceleration of GW’s oncology research interests and over the coming months, we expect to consult with external experts and regulatory agencies on a pivotal clinical development program for THC:CBD in GBM and to expand our research interests in other forms of cancer.”
Those who read Dabs Magazine religiously may notice that this is the second story concerning GW Pharma that we’ve run this week. The other speculated on GW’s subsidiary Greenwich BioSciences and its attempt to create legal CBD monopolies in South Dakota and Nebraska. So, they’re evil but they also cure cancer. Kind of a ying-yang company.
Photo via Flickr user NICHD